Appendix E - National Coverage Determinations Manual / FDG_PET_FOR_DEMENTIA_AND_NEURODEGENERATIVE_DISEASES

Why This Topic Matters

Coverage rules for advanced imaging in dementia workups affect medical necessity review, documentation practices, and claims compliance. Understanding the scope of this NCD helps organizations determine when the article is relevant to billing, ordering, and policy review.

Article Sections

1. A. General

   Introduces the overall scope of the national coverage policy and the two broad circumstances addressed in the article.

2. B. Nationally Covered Indications

   Outlines the covered settings and the accompanying requirements discussed for dementia-related FDG-PET use, including documentation and trial-related conditions.

3. 1. FDG-PET Requirements for Coverage in the Differential Diagnosis of AD and FTD

   Covers the diagnostic context, clinical evaluation elements, provider qualifications, and recordkeeping topics associated with this covered indication.

4. 2. FDG-PET Requirements for Coverage in the Context of a CMS-approved Practical Clinical Trial Utilizing a Specific Protocol to Demonstrate the Utility of FDG-PET in the Diagnosis, and Treatment of Neurodegenerative Dementing Diseases

   Summarizes the trial-based coverage context and the general protocol and oversight topics described for research settings.

5. C. Nationally Noncovered Indications

   Describes the categories of FDG-PET use that are stated as noncovered under the policy.

6. D. Other

   Provides the closing administrative note for the coverage determination.